{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T22:27:51Z","timestamp":1772231271569,"version":"3.50.1"},"reference-count":23,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No: 82072618"],"award-info":[{"award-number":["No: 82072618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Plan of SHDC","award":["No. SHDC2020CR1004A"],"award-info":[{"award-number":["No. SHDC2020CR1004A"]}]},{"name":"State Key Program of the National Natural Science Foundation of China","award":["No: 81730097"],"award-info":[{"award-number":["No: 81730097"]}]},{"name":"Science and Technology Commission Foundation of Shanghai Municipality","award":["No: 19411967300"],"award-info":[{"award-number":["No: 19411967300"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,9,27]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vascular invasion and metastasis are poor prognostic factors in patients with hepatocellular carcinoma (HCC). The efficacy of available therapeutic regimens for unresectable HCC is not satisfactory in HCC with portal vein tumour thrombosis (PVTT). Therefore, this open-label, single-arm phase II clinical trial aims to investigate the efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating HCC patients with PVTT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>We plan to enrol patients diagnosed with unresectable HCC complicated by PVTT. Intensity-modulated radiotherapy (IMRT) combined with atezolizumab plus bevacizumab will be administered for treatment. Patients will initially receive radiotherapy, with each IMRT cycle lasting for 28 days and the total dose of tumour (DT) of 40 Gy\/20 f\/26 d. CT scan will be performed again, and the treatment plan will be reformulated after field constriction. The treatment will continue until the total DT is up to 54\u201356\u2009Gy\/27\u201328\u2009f. The treatment with atezolizumab plus bevacizumab will be started at 3\u00b11\u2009days after the initiation of radiotherapy and will continue until unacceptable toxicity or disease progression. The primary endpoint is objective response rate (ORR), while the secondary endpoints include overall survival, disease control rate, progression-free survival, time to progression, duration of response and the rate of surgical conversions. Assuming an ORR of 47%, with a one-sided alpha error of 0.1, 90% power, and a 10% drop-out rate, the required number of evaluable patients is 42.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>This study will be conducted according to the standards of Good Clinical Practice and in compliance with the principles of the Declaration of Helsinki. The Ethics Committee of our Hospital has approved the protocol (EHBHKY2021-K-017). All participants are required to provide written informed consent. The results of the trial will be published in peer-reviewed journals and presented at international conferences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>ChiCTR2100049831.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-064688","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T17:13:54Z","timestamp":1671124434000},"page":"e064688","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol"],"prefix":"10.1136","volume":"12","author":[{"given":"Kang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Jun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Qiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-Zhi","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Xing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-8028","authenticated-orcid":false,"given":"Shu-Qun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"2024061819401038000_12.12.e064688.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2024061819401038000_12.12.e064688.2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.21147\/j.issn.1000-9604.2018.06.01","article-title":"Liver cancer incidence and mortality in China: temporal trends and projections to 2030","volume":"30","author":"Zheng","year":"2018","journal-title":"Chin J Cancer Res"},{"key":"2024061819401038000_12.12.e064688.3","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2024061819401038000_12.12.e064688.4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour evolution in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024061819401038000_12.12.e064688.5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000449343","article-title":"Hepatocellular carcinoma: therapeutic guidelines and medical treatment","volume":"6","author":"Kudo","year":"2016","journal-title":"Liver Cancer"},{"key":"2024061819401038000_12.12.e064688.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2024061819401038000_12.12.e064688.7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijsu.2015.05.009","article-title":"The strategies for treating primary hepatocellular carcinoma with\u00a0portal vein tumor thrombus","volume":"20","author":"Zhang","year":"2015","journal-title":"Int J Surg"},{"key":"2024061819401038000_12.12.e064688.8","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199808000-00014"},{"key":"2024061819401038000_12.12.e064688.9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2468-1253(19)30178-5","article-title":"Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing East and West","volume":"4","author":"Lu","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024061819401038000_12.12.e064688.10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086"},{"key":"2024061819401038000_12.12.e064688.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"2024061819401038000_12.12.e064688.12","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-010-9165-7"},{"key":"2024061819401038000_12.12.e064688.13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024061819401038000_12.12.e064688.14","doi-asserted-by":"crossref","first-page":"40816","DOI":"10.18632\/oncotarget.8386","article-title":"Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"2024061819401038000_12.12.e064688.15","doi-asserted-by":"publisher","DOI":"10.1159\/000514174"},{"key":"2024061819401038000_12.12.e064688.16","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-480"},{"key":"2024061819401038000_12.12.e064688.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2034"},{"key":"2024061819401038000_12.12.e064688.18","doi-asserted-by":"publisher","DOI":"10.7150\/thno.32648"},{"key":"2024061819401038000_12.12.e064688.19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4143\/crt.2013.142","article-title":"Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma","volume":"46","author":"Yu","year":"2014","journal-title":"Cancer Res Treat"},{"key":"2024061819401038000_12.12.e064688.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.01.017"},{"key":"2024061819401038000_12.12.e064688.21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122912","article-title":"Is the concurrent use of sorafenib and external radiotherapy feasible for advanced hepatocellular carcinoma? A meta-analysis","volume":"13","author":"Rim","year":"2021","journal-title":"Cancers"},{"key":"2024061819401038000_12.12.e064688.22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081901","article-title":"Outcomes and toxicities of modern combined modality therapy with Atezolizumab plus bevacizumab and radiation therapy for hepatocellular carcinoma","volume":"14","author":"Manzar","year":"2022","journal-title":"Cancers"},{"key":"2024061819401038000_12.12.e064688.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/9943683","article-title":"Combination intensity-modulated radiotherapy and sorafenib improves outcomes in hepatocellular carcinoma with portal vein tumor thrombosis","volume":"2021","author":"Abulimiti","year":"2021","journal-title":"J Oncol"}],"updated-by":[{"DOI":"10.1136\/bmjopen-2022-064688corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-064688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T02:40:34Z","timestamp":1718764834000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-064688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,15]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/bmjopen-2022-064688"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064688","relation":{"correction":[{"id-type":"doi","id":"10.1136\/bmjopen-2022-064688corr1","asserted-by":"object"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}